The Clinical &Translational Research Center (CTRC), established in 1990 and rated Outstanding in the 2008 CCSG review, focuses on new drug development. This comprehensive 18-bed combined treatment and laboratory unit serves as the primary site for personalized, protocol-based, innovative clinical and translational research. Services provided are research infrastructure and oversight as well as 24-hour phlebotomy/lab support for pharmacologic testing. Other services include specialized processing for DNA and RNA analysis, real-time internet-based tracking of audit time-points, Ei

Public Health Relevance

The CTRC is the primary site of new drug studies for cancer and related diseases, and since 2007 it has activated 274 protocols - including many first-in-man studies. Seventeen (17) drugs approved by the FDA since 2007 were studied in Phase I or II trials in the CTRC. NIH Cooperative Group and NCI protocols represented 11% of studies activated during the grant period and MD Anderson investigator initiated studies comprised 5%. Of the total 4,057 protocol registrations, NIH peer-reviewed studies accounted for 531 (13%).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759805
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$296,418
Indirect Cost
$111,234
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Rausch, Caitlin R; DiPippo, Adam J; Bose, Prithviraj et al. (2018) Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 67:1610-1613
Gu, Shenda; Ngamcherdtrakul, Worapol; Reda, Moataz et al. (2018) Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS One 13:e0198141
Fountzilas, Elena; Said, Rabih; Tsimberidou, Apostolia M (2018) Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert Opin Investig Drugs 27:155-162
Blanchard, Pierre; Davis, John W; Frank, Steven J et al. (2018) Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int 121:540-548
Niknam, Sharareh; Barsoumian, Hampartsoum B; Schoenhals, Jonathan E et al. (2018) Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res 24:5735-5743
Kamal, Mona; Ng, Sweet Ping; Eraj, Salman A et al. (2018) Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol 79:1-8
Housten, Ashley J; Pappadis, Monique R; Krishnan, Shilpa et al. (2018) Resistance to discontinuing breast cancer screening in older women: A qualitative study. Psychooncology 27:1635-1641
Hsu, Jung-Mao; Xia, Weiya; Hsu, Yi-Hsin et al. (2018) STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun 9:1908
Akay, Catherine L; Albarracin, Constance; Torstenson, Tiffany et al. (2018) Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J 24:28-34
Khong, Hiep; Volmari, Annika; Sharma, Meenu et al. (2018) Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. J Immunol 200:3464-3474

Showing the most recent 10 out of 12418 publications